Integra LifeSciences Holdings Corp., a Plainsboro-based medical technology company, announced Monday it has acquired Arkis Biosciences Inc., a Knoxville, Tennessee-based company that offers a portfolio of neurosurgical devices.
The portfolio includes the CerebroFlo external ventricular drainage catheter with Endexo technology, a permanent additive that helps reduce the potential for catheter obstruction due to the formation of thrombus.
The acquisition will help strengthen Integra’s neurocritical care offerings and position it higher as a provider of advanced catheter technology, Integra said.
“The introduction of the CerebroFlo EVD Catheter first established the benefits of Endexo in neurocritical care,” Chad Seaver, CEO, Arkis Biosciences, said. “As a world leader in neurosurgery, Integra is the right choice to extend the reach of this important technology to patients and clinicians worldwide.”
Financial terms were not disclosed.
